Evidence map›Paper›PMID 30499047›Full record

ReviewNano convergence2018

Therapeutic nanoplatforms and delivery strategies for neurological disorders.

You Jung Kang, Eric Gerard Cutler, Hansang Cho

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nano convergence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. The Role of Nanotechnology in Understanding the Pathophysiology of Traumatic Brain Injury.Central nervous system agents in medicinal chemistry · 2025
    Review
  13. Review
  14. Progress of nanoparticle drug delivery system for the treatment of glioma.Frontiers in bioengineering and biotechnology · 2024
    Review
  15. Review
  16. Review
  17. Cytotoxic Potential ofPlants (Basel, Switzerland) · 2023
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

You Jung KangDepartment of Mechanical Engineering and Engineering Science, Center for Biomedical Engineering and Science, Department of Biological Sciences, The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA.
Eric Gerard CutlerDepartment of Mechanical Engineering and Engineering Science, Center for Biomedical Engineering and Science, Department of Biological Sciences, The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA.
Hansang ChoDepartment of Mechanical Engineering and Engineering Science, Center for Biomedical Engineering and Science, Department of Biological Sciences, The Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, NC, USA. h.cho@uncc.edu.ORCID http://orcid.org/0000-0003-1829-2462
University of North Carolina at Charlotte · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major neurological disorders found in a central nervous system (CNS), such as brain tumors, Alzheimer's diseases, Parkinson's diseases, and Huntington's disease, have led to devastating outcomes on the human public health. Of these disorders, early diagnostics remains poor, and no treatment has been successfully discovered; therefore, they become the most life-threatening medical burdens worldwide compared to other major diseases. The major obstacles for the drug discovery are the presence of a restrictive blood-brain barrier (BBB), limiting drug entry into brains and undesired neuroimmune activities caused by untargeted drugs, leading to irreversible neuronal damages. Recent advances in nanotechnology have contributed to the development of novel nanoplatforms and effective delivering strategies to improve the CNS disorder treatment while less disturbing brain systems. The nanoscale drug carriers, including liposomes, dendrimers, viral capsids, polymeric nanoparticles, silicon nanoparticles, and magnetic/metallic nanoparticles, enable the effective drug delivery penetrating across the BBB, the aforementioned challenges in the CNS. Moreover, drugs encapsulated by the nanocarriers can reach further deeper into targeting regions while preventing the degradation. In this review, we classify novel disease hallmarks incorporated with emerging nanoplatforms, describe promising approaches for improving drug delivery to the disordered CNS, and discuss their implications for clinical practice.

Indexed as

Alzheimer’s diseases (AD)BiomarkerBlood–brain barrier (BBB)Central nervous system (CNS)Drug deliveryGlioblastoma (GBM)NanomedicineNanoparticleNeurological diseasesParkinson’s diseases (PD)Targeted delivery

Identifiers

PMID30499047
PMCPMC6265354
OpenAlexW2903560142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.